Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea-Reference-Cited by-同舟云学术

Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea

Published:2024 Issue: Volume:39 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Huh Kyungmin¹^ORCID,Jo Youngji²^ORCID,Bae Gi Hwan³^ORCID,Joo Hyejin⁴^ORCID,Radnaabaatar Munkhzul³^ORCID,Lee Hyungmin⁵⁶^ORCID,Kim Jungyeon⁵⁷^ORCID,Kim Dong-Hwi⁵^ORCID,Yoo Min-Gyu⁵⁸^ORCID,Jo Il Uk⁹^ORCID,Lee Poong Hoon⁹^ORCID,Lee Geun Woo⁹^ORCID,Jung Hee Sun⁹^ORCID,Jung Jaehun³⁴^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Department of Public Health Sciences, School of Medicine, University of Connecticut, CT, USA.

3. Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

4. Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea.

5. Patient Management Team, Central Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.

6. Division of Immunization, Korea Disease Control and Prevention Agency, Cheongju, Korea.

7. Division of Clinical Research, Center for Emerging Virus Research, National Institute of Infectious Disease, Korea Disease Control and Prevention Agency, Cheongju, Korea.

8. Division of Public Health Emergency Response Research, Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Korea.

9. Big Data Management Division, Health Insurance Review & Assessment Service, Wonju, Korea.

Funder

Korea National Institute of Health

National Research Foundation of Korea

Publisher

XMLink

Link

https://jkms.org/pdf/10.3346/jkms.2024.39.e272

Reference22 articles.

1. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

2. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews

3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

5. Pfizer. Highlights of prescribing information (paxlovid). Updated 2023. Accessed December 10, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf